Clin2
NCT06723080Likely a fitRecruiting

Oral VC005 for moderate to severe eczema

Moderate to Severe Atopic Dermatitis

Part of Skin clinical trials.

This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
480 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have had atopic dermatitis (eczema) for at least 1 year.
  • Your eczema is moderate to severe (covering at least 10% of your body or a severity score of 3 or higher).
  • You have tried topical treatments (creams or ointments) in the past year that did not work well enough or caused side effects.
  • You are between 18 and 75 years old.
  • You do not have certain medical conditions like a history of blood clots, herpes infections, or cancer (except for some minor skin cancers).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07465120Not yet recruiting· Phase 2
Testing CMS-D001 for moderate to severe eczema

This study tests a new medicine called CMS-D001 for adults with moderate to severe eczema (atopic dermatitis) that hasn't improved enough with standard creams. Participants will receive either CMS-D001 or a placebo to see if it helps reduce itching and skin symptoms.

Beijing, Beijing Municipality
NCT07370909Recruiting· Phase 3
Oral LW402 for moderate-to-severe eczema

This trial tests an oral pill called LW402 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug is safe and effective at reducing skin symptoms.

Beijing
NCT07592585Recruiting· Phase 3
Testing VC005 cream for mild-to-moderate eczema in teens and adults

This study tests a new medication called VC005 to treat atopic dermatitis (eczema)—a skin condition causing itching, redness, and inflammation. Researchers want to see if VC005 can safely reduce symptoms in people aged 12 and older with mild-to-moderate cases.

Nanjing, Jiangsu
NCT07598383Recruiting· Phase 2
Gel treatment for mild-to-moderate atopic dermatitis

This study tests a new gel called VC005 to see if it safely reduces itching, redness, and irritation in people with atopic dermatitis (a chronic skin condition). You'll be randomly assigned to either the new gel or a placebo (inactive gel) and apply it to affected areas over several weeks.

Hangzhou, Zhejiang
NCT06775860Recruiting· Phase 3
Testing ICP-332 for moderate to severe eczema

This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.

Hefei, Anhui
NCT07175233Not yet recruiting· Phase 2
Study of SIM0278 for moderate to severe eczema

This trial tests an experimental drug called SIM0278 for people with moderate to severe atopic dermatitis (eczema). It aims to see if the drug can reduce skin symptoms and is safe to use.

Hangzhou

Hear when a new Moderate to Severe Atopic Dermatitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.